A phase I trial of the γ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).

被引：3
|
作者：
Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, Thomas Jeff
Steward, William P.
Hagemann, Thorsten
Venugopal, Balaji
Tuveson, David A.
Hategan, Mirela
Anthoney, David Alan
Farmer, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah E. R.
Jodrell, Duncan Ian
机构：
[1] Univ Cambridge, Cambridge Res Inst, Canc Res UK, Cambridge, England
[2] Cambridge Univ NHS Fdn Trust, Addenbrookes Hosp, Dept Oncol, Cambridge, England
[3] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge, England
[4] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[5] Univ Leicester, Dept Oncol, Leicester, Leics, England
[6] Univ London, Barts Canc Inst, London, England
[7] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[8] Cold Spring Harbor Labs, New York, NY USA
[9] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England
[10] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[11] Canc Res UK, Drug Dev Off, London, England
[12] Canc Res UK, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4116
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Park, Byeong-Bae
    Park, Joon Oh
    Lee, Hyo Rak
    Lee, Jeeyun
    Choi, Dong Wook
    Choi, Seong-Ho
    Heo, Jin Seok
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lim, Do Hoon
    Park, Young Suk
    Lim, Ho-Yeong
    Kang, Won Ki
    Park, Keunchil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (04) : 489 - 494
  • [42] Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
    Kim, G. P.
    Oberg, A. L.
    Foster, N. R.
    Jaslowski, A.
    Flynn, P. J.
    Campbell, D.
    Hedrick, E.
    Gray, L.
    Grothey, A.
    Alberts, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
    Byeong-Bae Park
    Joon Oh Park
    Hyo Rak Lee
    Jeeyun Lee
    Dong Wook Choi
    Seong-Ho Choi
    Jin Seok Heo
    Jong Kyun Lee
    Kyu Taek Lee
    Do Hoon Lim
    Young Suk Park
    Ho-Yeong Lim
    Won Ki Kang
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 489 - 494
  • [44] Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma
    Wolff, RA
    Evans, DB
    Gravel, DM
    Lenzi, R
    Pisters, PWT
    Lee, JE
    Janjan, NA
    Charnsangavej, C
    Abbruzzese, JL
    CLINICAL CANCER RESEARCH, 2001, 7 (08) : 2246 - 2253
  • [45] Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)
    Bajor, David Lawrence
    Gutierrez, Martin
    Vaccaro, Gina M.
    Masood, Ashiq
    Brown-Glaberman, Ursa
    Grilley-Olson, Juneko E.
    Kindler, Hedy L.
    Zalupski, Mark
    Heath, Elisabeth I.
    Piha-Paul, Sarina Anne
    Zhou, Peigen
    Lu, Hailing
    Ansari, Sahar
    Hayman, Jonathan
    Schmitt, Michael W.
    Coveler, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [46] Phase I trial of imexon, Inj. plus gemcitabine in patients with advanced previously untreated pancreatic adenocarcinoma
    Cohen, S. J.
    Zalupski, M.
    Modiano, M.
    Conkling, P.
    Mahadevan, D.
    Wong, L.
    Smith, D.
    Dorr, R. T.
    Boytim, M.
    Hersh, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
    Mahalingam, Devalingam
    Goel, Sanjay
    Aparo, Santiago
    Arora, Sukeshi Patel
    Noronha, Nicole
    Hue Tran
    Chakrabarty, Romit
    Selvaggi, Giovanni
    Gutierrez, Andres
    Coffey, Matthew
    Nawrocki, Steffan T.
    Nuovo, Gerard
    Mita, Monica M.
    CANCERS, 2018, 10 (06)
  • [48] A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).
    Aung, Kyaw Lwin
    McWhirter, Elaine
    Welch, Stephen
    Wang, Lisa
    Lovell, Sophia
    Stayner, Lee-Anne
    Ali, Saara
    Malpage, Anne
    Makepeace, Barbara
    Ramachandran, Makilpriya
    Dhani, Neesha C.
    Hedley, David W.
    Knox, Jennifer J.
    Siu, Lillian L.
    Goodwin, Rachel Anne
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
    Kim, Edward J.
    Sahai, Vaibhav
    Abel, Ethan V.
    Griffith, Kent A.
    Greenson, Joel K.
    Takebe, Naoko
    Khan, Gazala N.
    Blau, John L.
    Craig, Ronald
    Balis, Ulysses G.
    Zalupski, Mark M.
    Simeone, Diane M.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5937 - 5945
  • [50] Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
    Daud, Adil I.
    Ashworth, Michelle T.
    Strosberg, Jonathan
    Goldman, Jonathan W.
    Mendelson, David
    Springett, Gregory
    Venook, Alan P.
    Loechner, Sabine
    Rosen, Lee S.
    Shanahan, Frances
    Parry, David
    Shumway, Stuart
    Grabowsky, Jennifer A.
    Freshwater, Tomoko
    Sorge, Christopher
    Kang, Soonmo Peter
    Isaacs, Randi
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 1060 - +
12345